We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-2.68%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$17.3B
AUM Growth
-$1.1B
Cap. Flow
-$283M
Cap. Flow %
-1.64%
Top 10 Hldgs %
87.61%
Holding
112
New
6
Increased
21
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
KYMR icon
Kymera Therapeutics
KYMR
+$42.9M
2
ROIV icon
Roivant Sciences
ROIV
+$41.6M
3
ABCL icon
AbCellera Biologics
ABCL
+$40.9M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$20.6M
5
IMGN
Immunogen Inc
IMGN
+$17.9M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$469M
2
KYNB
Kyntra Bio
KYNB
+$39.7M
3
BPMC
Blueprint Medicines
BPMC
+$15M
4
KRYS icon
Krystal Biotech
KRYS
+$13.6M
5
VSTM icon
Verastem
VSTM
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 99.14%
2 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTX icon
101
Nkarta
NKTX
$155M
$594K ﹤0.01%
271,329
-128,671
-32% -$566K
TARA icon
102
Protara Therapeutics
TARA
$218M
$477K ﹤0.01%
199,671
– –
GTH
103
DELISTED
Genetron Holdings Limited ADS
GTH
$423K ﹤0.01%
151,769
– –
FHTX icon
104
Foghorn Therapeutics
FHTX
$290M
$317K ﹤0.01%
45,027
– –
VINC
105
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$293K ﹤0.01%
11,279
-790
-7% -$22.6K
SRZNW icon
106
Surrozen Inc Warrant
SRZNW
$36.6K
$46K ﹤0.01%
833,333
– –
ATRA icon
107
Atara Biotherapeutics
ATRA
$74.3M
– –
-29,767
Closed -$2.16M
BPMC
108
DELISTED
Blueprint Medicines
BPMC
– –
-333,665
Closed -$15M
VERU icon
109
Veru
VERU
$36M
– –
-160,958
Closed -$1.87M
BLCM
110
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
– –
-249,123
Closed -$82.2K
TCRR
111
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
– –
-753,064
Closed -$1.13M
1 2 3 4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2023 Portfolio in Review

As of Q2 2023, Baker Bros. Advisors held 112 positions worth $17.3B, down 6% from $18.4B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Baker Bros. Advisors's Q2 2023 filing shows 6 new, 21 increased, 12 reduced and 5 closed positions. Its largest new stake was Immunogen Inc: 1,520,097 shares worth $28.7M. The largest sale was Seagen Inc. Common Stock, an estimated $469M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q2 2023 buy was Immunogen Inc: 1,520,097 shares worth $28.7M.
  • Baker Bros. Advisors added most to Kymera Therapeutics in Q2 2023, an estimated $42.9M increase.
  • Baker Bros. Advisors's biggest Q2 2023 reduction was Seagen Inc. Common Stock, cutting an estimated $469M.
  • Baker Bros. Advisors fully exited Blueprint Medicines in Q2 2023, selling an estimated $15M.
  • Baker Bros. Advisors's ten largest holdings make up 88% of its $17.3B portfolio in Q2 2023.
  • Baker Bros. Advisors opened 6 new positions and closed 5 in Q2 2023.
  • Baker Bros. Advisors's portfolio value fell 6% quarter-over-quarter to $17.3B.

Based on Baker Bros. Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.